Advances of the interleukin‑21 signaling pathway in immunity and angiogenesis (Review)
- Authors:
- Published online on: April 27, 2016 https://doi.org/10.3892/br.2016.665
- Pages: 3-6
Abstract
Introduction
Interleukin-21 (IL-21) and its receptor (IL-21R) were identified in 2000 (1). IL-21 is primarily produced by cluster of differentiation 4+ (CD4+) cells and natural killer cells, while IL-21R is broadly expressed on human B cells, activated T cells and other myeloid cells (2,3). IL-21 is a pleiotrophic cytokine that is composed of four α-helical bundles. IL-21R shares the common cytokines receptor γ chain (γc) with the IL-2 family cytokines, such as IL-4, IL-7, IL-9 and IL-15 (4). In addition, IL-21R has a distinct α chain, and contains six tyrosine residues in the cytoplasmic domain (3,5). This specific IL-21R structure differentiates IL-21R from IL-2R. IL-21 exerts its effect on a broad range of cell types. Increasing evidence shows that IL-21 potently regulates innate and adaptive immune response (6–8). Furthermore, the role of IL-21 in angiogenesis has also been studied (9,10). In the present review, the recent advances regarding the role of IL-21 in immune cells and angiogenesis are discussed.
Function of IL-21 on immune cells
Although IL-21 is not required for CD4+ T-cell development, it contributes to the functional differentiation of several subsets (11,12), such as T helper 2 (Th2) cells (13,14), Th17 (15,16) and follicular helper T (Tfh) cells (17,18). Th17 and Tfh cells can be generated in the absence of IL-21/IL-21R (16), indicating an IL-21-independent pathway for their development. IL-21 is produced by the Th17 cells, and transforming growth factor-β (TGF-β) and IL-6 can activate Th17 cells even in the absence of IL-21 (19,20). IL-21 regulates the transcription factors B-cell lymphoma 6 (BCL-6) and MAF, which are important to the transcriptional programme of the Tfh cells (21,22). IL-6 can induce Tfh-cell differentiation via its induction of IL-21 production. The number of Treg cells is increased in IL-21- and IL-6-knockout mice, and TGF-β signaling enhances the generation of Treg cells in the absence of either IL-21 or IL-6 (23,24). Thus, IL-21 appears to have a complementary role in regulating CD4+ T-cell differentiation.
B-cell expression of IL-21R notably exceeds that of T cells. A large number of studies confirm that IL-21 involved in the regulation of both B cell proliferation and maturation. IL-21 can stimulate B cells proliferation and differentiation in the context of a co-stimulatory T-cell signal. IL-21-mediated human B-cell differentiation requires signal transducer and activator of transcription 3 (STAT3), and cannot be compensated by alternative signaling pathways (25). The effect of IL-21 can be augmented by IL-2 or IL-10, and IL-21 induces IL-10 in human B cells and interacts with TGF-β (26,27). In particular, IL-21 promotes B cells differentiation to Ig-producing plasma through its induction of B lymphocyte-induced maturation protein-1 (28), which is a transcription factor critical for plasma cell formation. Notably, IL-21 also induces B cell apoptosis either in the absence of a T-cell signal or in the activation of a Toll-like receptor signal (29). The pro-apoptotic activity of IL-21 results from the induction of BCL-2, which is a pro-apoptotic protein.
IL-21 has broad actions on T and B cells, but its innate immunity is poorly understood. IL-21 has a potent inhibitory effect on granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced dendritic cells (DCs) (30). IL-21 induces apoptosis of conventional DCs (cDCs) via STAT3 and inhibiting Bim, and this effect is prevented by GM-CSF, which partially opposes the biological action by these cytokines. Furthermore, the number of STAT3 sites was reduced in the presence of GM-CSF when DCs were treated with IL-21, and GM-CSF primarily activates STAT5 instead of STAT3 and inhibits Bim (31). These findings suggest that IL-21-induced STAT3-dependent apoptosis of DCs provides a mechanism for alleviating the immune response, and IL-21 has a cross-negative regulation with GM-CSF.
Signaling by IL-21
IL-21 regulates the innate and adaptive immune responses via heterodimers of the IL-21R and the common cytokine receptor γc1. IL-21 signals via the Janus kinase (JAK)-STAT signaling pathway (25,26), the mitogen-activated protein kinase signaling pathway and the phosphoinositide 3-kinase-AKT signaling pathway (2). Of these, the JAK-STAT pathway has been the most extensively studied. In T cells, IL-21 activates STAT3 more than STAT1 and STAT5. STAT1 and STAT3 have partially opposing roles in IL-21 signaling. RNA-sequence analysis showed that STAT1 and STAT3 are critical for IL-21-mediated gene regulation, including Tbx21 and interferon γ (32). Notably, IL-21-induced expression of suppressor of cytokine signaling 3 (Socs3) and Socs1 are decreased in Stat3−/− cells (33). SOCS3 and SOCS1 can negatively regulate STAT protein phosphorylation, and this may in part explain the opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. In cDCs, IL-21 induces IL-1β production via a STAT3 dependent and nuclear factor-κB independent pathway. Furthermore, this processing in cDCs does not require caspase-1 or caspase-8, but depends on IL-21-mediated death (34). IL-21 can induce the expression of PR domain containing 1, with ZNF domain in multiple B lymphoma cell lines, and IL-21 induces STAT3 binding also bound interferon regulatory factor 4 (IRF4) in vivo (35,36), and Irf4−/− mice showed impaired IL-21 induced Tfh cells differentiation (37). These results reveal broad cooperative gene regulation by STAT3 and IRF4. In T cells, numerous target genes of IL-21 are regulated through basic leucine zipper transcription factor, ATF-like, JUN, IRF4 and STAT3 (37,38). Notably, these transcription factors are also potential targets through which IL-21 signaling may be regulated. Our recent study reported that IL-21 activated STAT3 in HUVECs exposed to ischemia conditions; however, there were no significant changes in STAT1, AKT1 or extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation at any time point following IL-21 treatment (9).
IL-21 and angiogenesis
It has been shown that IL-21R exists in endothelial cells (ECs), which is a key process in the formation of new blood vessels during angiogenesis. IL-21 treatment decreases EC proliferation and sprouting in vitro. Furthermore, in a tumor mouse model, IL-21 inhibited tumor angiogenesis in vivo and decreased angiogenesis vascular endothelial growth factor A and its receptors (10). Another study demonstrated conflicting results, in which genetic ablation of IL-21 in Apcmin/+ mice reduced STAT3 activation and diminished cytokines, including IL-6 and tumor necrosis factor-α, and decreased angiogenesis in the lesions (8).
In our recent study of a mouse model with surgical hindlimb ischemia (HLI), the IL-21R levels were higher in the EC-enriched fraction isolated from ischemic hindlimb muscle. Furthermore, HUVECs showed 10-fold IL-21R expression following hypoxia and serum starvation in vitro. IL-21 treatment increased cell viability, decreased cell apoptosis and augmented tube formation in HUVECs under ischemic conditions. Knockout IL-21R resulted in less perfusion recovery following HLI in vivo. In particular, the activated STAT3 pathway and increase in the BCL-2/BCL-2-associated X protein ratio were involved in the in vitro and in vivo experiments (9). These results suggest that the elevated IL-21R levels in EC in ischemia muscle are adaptive.
Potential therapeutic effect of IL-21
Numerous studies have shown that IL-21 has therapeutic effects in animal models of a wide range of diseases [including cancer (12), immunity-deficient disease (39), type 1 diabetes (40) and inflammatory bowel disease (41)] and various clinical trials are underway (42).
An investigation regarding the association between IL-21 levels and myocardial function following acute myocardial showed that plasma IL-21 concentration correlated significantly with left ventricular end-systolic volume index, and multivariate analysis suggested that IL-21 was an independent predictor of remodeling. Furthermore, IL-21 was also significantly associated with higher tissue inhibitor of metalloproteinases-4 (TIMP-4) concentrations and lower MMP-9 concentrations (43). A previous experiment demonstrated that IL-21R was expressed on cardiac fibroblasts (44), and whether IL-21 may directly stimulate MMP/TIMP release within the myocardium is unknown and merits further study.
Conclusion
IL-21 has been implicated in broad immunological processes since its discovery in 2000. IL-21 regulates at least 3 pathways (STAT3, ERK1/2 and AKT-1), which can either enhance cell survival or pro-apoptosis in different cell lines. IL-21 signaling pathways are complex due to their cooperation with other transcriptional factors. With the improvement of our understanding in IL-21 biology regarding each specific disease or pathological condition, IL-21 could be a new therapeutic target for immune relative disease.
Acknowledgements
The present study was partially supported by National Natural Science Foundation of China (grant no. 81300315)
References
|
Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 408:57–63. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Spolski R and Leonard WJ: Interleukin-21: A double-edged sword with therapeutic potential. Nat Rev Drug Discov. 13:379–395. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mehta DS, Wurster AL and Grusby MJ: Biology of IL-21 and the IL-21 receptor. Immunol Rev. 202:84–95. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ozaki K, Kikly K, Michalovich D, Young PR and Leonard WJ: Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA. 97:11439–11444. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D and Sugamura K: Cutting edge: The common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 167:1–5. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Spolski R and Leonard WJ: Interleukin-21: Basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 26:57–79. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelzang A, McGuire HM, Liu SM, Gloss B, Mercado K, Earls P, Dinger ME, Batten M, Sprent J and King C: IL-21 contributes to fatal inflammatory disease in the absence of Foxp3+ T regulatory cells. J Immunol. 192:1404–1414. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
De Simone V, Ronchetti G, Franzè E, Colantoni A, Ortenzi A, Fantini MC, Rizzo A, Sica GS, Sileri P, Rossi P, et al: Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. Oncotarget. 6:9908–9923. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kanada M, Bachmann MH, Hardy JW, Frimannson DO, Bronsart L, Wang A, Sylvester MD, Schmidt TL, Kaspar RL, Butte MJ, et al: Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci USA. 112:E1433–E1442. 2015.PubMed/NCBI | |
|
Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA and Griffioen AW: Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 112:4940–4947. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Leonard WJ and Spolski R: Interleukin-21: A modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 5:688–698. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Davis MR, Zhu Z, Hansen DM, Bai Q and Fang Y: The role of IL-21 in immunity and cancer. Cancer Lett. 358:107–114. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, Cheever AW, Young DA, Collins M, Grusby MJ and Wynn TA: The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest. 116:2044–2055. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fröhlich A, Marsland BJ, Sonderegger I, Kurrer M, Hodge MR, Harris NL and Kopf M: IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood. 109:2023–2031. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ and Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8:967–974. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, et al: Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 448:480–483. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, et al: Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 29:138–149. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Eto D, Lao C, DiToro D, Barnett B, Escobar TC, Kageyama R, Yusuf I and Crotty S: IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One. 6:e177392011. View Article : Google Scholar : PubMed/NCBI | |
|
Karnowski A, Chevrier S, Belz GT, Mount A, Emslie D, D'Costa K, Tarlinton DM, Kallies A and Corcoran LM: B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med. 209:2049–2064. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kastirr I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, Crosti MC, Moro M, Steckel B, Steinfelder S, et al: IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol. 193:3322–3331. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH and Kuchroo VK: The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol. 10:167–175. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH and Dong C: Bcl6 mediates the development of T follicular helper cells. Science. 325:1001–1005. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M and Kuchroo VK: IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 448:484–487. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, Kopf M and Walker LS: IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood. 119:4656–4664. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Berglund LJ, Avery DT, Ma CS, Moens L, Deenick EK, Bustamante J, Boisson-Dupuis S, Wong M, Adelstein S, Arkwright PD, et al: IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood. 122:3940–3950. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deenick EK, Avery DT, Chan A, Berglund LJ, Ives ML, Moens L, Stoddard JL, Bustamante J, Boisson-Dupuis S, Tsumura M, et al: Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med. 210:2739–2753. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Avery DT, Bryant VL, Ma CS, de Waal Malefyt R and Tangye SG: IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol. 181:1767–1779. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, et al: Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 173:5361–5371. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu BS, Stoop JN, Huizinga TW and Toes RE: IL-21 enhances the activity of the TLR-MyD88-STAT3 pathway but not the classical TLR-MyD88-NF-κB pathway in human B cells to boost antibody production. J Immunol. 191:4086–4094. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Brandt K, Bulfone-Paus S, Foster DC and Rückert R: Interleukin-21 inhibits dendritic cell activation and maturation. Blood. 102:4090–4098. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wan CK, Oh J, Li P, West EE, Wong EA, Andraski AB, Spolski R, Yu ZX, He J, Kelsall BL, et al: The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity. 38:514–527. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wan CK, Andraski AB, Spolski R, Li P, Kazemian M, Oh J, Samsel L, Swanson PA II, McGavern DB, Sampaio EP, et al: Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. Proc Natl Acad Sci USA. 112:9394–9399. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Strengell M, Lehtonen A, Matikainen S and Julkunen I: IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol. 79:1279–1285. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wan CK, Li P, Spolski R, Oh J, Andraski AB, Du N, Yu ZX, Dillon CP, Green DR and Leonard WJ: IL-21-mediated non-canonical pathway for IL-1β production in conventional dendritic cells. Nat Commun. 6:79882015. View Article : Google Scholar : PubMed/NCBI | |
|
Huber M, Brüstle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von Löw E and Lohoff M: IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci USA. 105:20846–20851. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, Carotta S, Donovan CE, Goldman ML, Tailor P, et al: Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity. 31:941–952. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Spolski R, Liao W, Wang L, Murphy TL, Murphy KM and Leonard WJ: BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature. 490:543–546. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, Van der Lugt B, Khan AA, Ciofani M, Spooner CJ, Rutz S, et al: A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science. 338:975–980. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kotlarz D, Ziętara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, Krawitz PM, Robinson PN, Hecht J, Puchałka J, et al: Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med. 210:433–443. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Spolski R, Kashyap M, Robinson C, Yu Z and Leonard WJ: IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA. 105:14028–14033. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Salzer E, Kansu A, Sic H, Májek P, Ikincioğullari A, Dogu FE, Prengemann NK, Santos-Valente E, Pickl WF, Bilic I, et al: Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol. 133:1651–1659.e12. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tangye SG: Advances in IL-21 biology-enhancing our understanding of human disease. Curr Opin Immunol. 34:107–115. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Weir RA, Miller AM, Petrie CJ, Clements S, Steedman T, Dargie HJ, Squire IB, Ng LL, McInnes IB and McMurray JJ: Interleukin-21 - a biomarker of importance in predicting myocardial function following acute infarction? Cytokine. 60:220–225. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, Caprioli F, Tersigni R, Alessandroni L, et al: Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut. 55:1774–1780. 2006. View Article : Google Scholar : PubMed/NCBI |
